Tackling Violence at Home 09-10 Action Plan

Tackling Violence at Home

Tackling Sexual Violence and Abuse 09-10 Action Plan

Tackling Sexual Violence and Abuse

Statistics on Smoking Cessation Services in Northern Ireland: 08/09: Pre Release Access List

2008/09 Pre-Release Access List

Strategic Resources Framework Report 2008/09 (PDF 532KB)

Strategic Resources Framework Report for 2008/09

Strategic Resources Framework Report 2008/09 - Appendices (PDF 892KB)

Appendices to the Strategic Resources Framework Report for 2008/09

Priorities for Action 2008-09 (PDF 146 KB)

Priorities for Action 2008/09

Older People's Commissioner for Wales - Annual Review 08/09 putting older people at our heart

The role of Older People's Commissioner for Wales was created with a range of powers to help improve the lives of older people in Wales. This is the first Commission of its kind. Many groups and individuals worked to bring this independent post into being, and the Commissioner's powers reflect their serious intent to challenge the barriers and discrimination that face older people.

Health inequalities: third report of session 2008-09, volume I

In the following report, chapter two examines the extent and causes of health inequalities. The causes of inequalities are broad and some of them reach beyond the capabilities and responsibilities of both the Department of Health and the NHS. This report therefore focuses on the effectiveness of the policies of the Department of Health and the NHS.

Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.

Tamoxifen (tam) is a widely used endocrine therapy in the treatment of early and advanced stage breast cancer in women and men. It is a pro-drug having weak affinity with the estrogen receptor and needs to be converted to its main metabolite, endoxifen (endox), to have full anticancer activity. Cytochrome 2D6 (CYP2D6) plays a major role in the metabolism of tamoxifen to endoxifen. It is genetically highly polymorphic and its activity influences profoundly the synthesis of endoxifen and potentially the efficacy of tamoxifen treatment. Genotyping is currently the most widely used approach in studies and also in clinical practice to categorize patients as poor- (PM), intermediate- (IM), extensive- (EM) and ultra rapid-metabolizers (UM). Some clinicians already use genotyping in order to tailor the endocrine therapy of their patients. Owing to the large inter-individual variations in concentrations of the active moitey due to genetic and non-genetic influences renders the predictive value of the test uncertain for an individual patient. A significant number of patients classified as EM or IM by genotyping have indeed relatively low endoxifen levels similar to PMs1. This suggests that genotyping is probably not the opti ma l meth o d f or predi cti ng end oxif en l evels.

Especial primavera 09: la atención a las alergias al polen

Boletín semanal para profesionales sanitarios de la Secretaría General de Salud Pública y Participación Social de la Consejería de Salud

La crisis económica y las desigualdades sociales, el cambio climático y la reforma de la salud pública, a debate en el Congreso SESPAS 09

Boletín semanal para profesionales sanitarios de la Secretaría General de Salud Pública y Participación Social de la Consejería de Salud